Successful allogeneic hematopoietic stem cell transplantation for aleukemic Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemo-radiotherapy for breast cancer-Reference-Cited by-同舟云学术

Successful allogeneic hematopoietic stem cell transplantation for aleukemic Philadelphia chromosome-positive acute lymphoblastic leukemia secondary to chemo-radiotherapy for breast cancer

Published:2018 Issue:4 Volume:7 Page:152-156
ISSN:2186-5612
Container-title:Journal of Hematopoietic Cell Transplantation
language:en
Short-container-title:Journal of Hematopoietic Cell Transplantation

Author:

Gotoh Yuta¹,Tsunemine Hiroko¹,Zushi Yuriko²,Aoyama Yumi¹,Kodaka Taiichi¹,Itoh Tomoo³,Takahashi Takayuki¹

Affiliation:

1. Department of Hematology, Shinko Hospital, Kobe, Japan

2. Department of Cell Therapy, Shinko Hospital, Kobe, Japan

3. Department of Diagnostic Pathology, Kobe University Graduate School of Medicine, Kobe, Japan

Publisher

The Japan Society for Hematopoietic Stem Cell Transplantation

Subject

General Medicine

Link

https://www.jstage.jst.go.jp/article/hct/7/4/7_18-001/_pdf

Reference18 articles.

1. 1. Borowitz MJ, Chan JKC, Downing JR, Le Beau MM, Arber DA. B-lymphoblastic leukaemia/lymphoma with recurrent genetic abnormalities. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. Revised 4th ed. Lyon, France, International Agency for Research on Cancer. 2017; 203-209.

2. 2. Kurzrock R, Shtalrid M, Romero P, et al. A novel c-abl protein product in Philadelphia-positive acute lymphoblastic leukaemia. Nature. 1987; 325: 631-635.

3. 3. Kantarjian HM, Talpaz M, Dhingra K, et al. Significance of the P210 versus P190 molecular abnormalities in adults with Philadelphia chromosome-positive acute leukemia. Blood. 1991; 78: 2411-2418.

4. 4. Thomas DA, Faderl S, Cortes J, et al. Treatment of Philadelphia chromosome-positive acute lymphocytic leukemia with hyper-CVAD and imatinib mesylate. Blood. 2004; 103: 4396-4407.

5. 5. Ravandi F, O’Brien S, Thomas D, et al. First report of phase 2 study of dasatinib with hyper-CVAD for the frontline treatment of patients with Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia. Blood. 2010; 116: 2070-2077.